Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.

Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV.

Brain. 1992 Dec;115 ( Pt 6):1701-25.

PMID:
1486457
3.

[Levodopa and cognitive disorders in Parkinson's disease].

Leiva-Santana C, Alvarez-SaĂșco M.

Rev Neurol. 2006 Jul 16-31;43(2):95-100. Review. Spanish.

4.

Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.

Cools R.

Neurosci Biobehav Rev. 2006;30(1):1-23. Epub 2005 Jun 1. Review.

PMID:
15935475
5.

[Parkinson disease and cognition].

Kulisevsky J, Pascual-Sedano B.

Neurologia. 1999 May;14 Suppl 1:72-81. Review. Spanish.

PMID:
10377731
6.

A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry.

Zgaljardic DJ, Borod JC, Foldi NS, Mattis P.

Cogn Behav Neurol. 2003 Dec;16(4):193-210. Review.

PMID:
14665819
7.

Dopamine and the regulation of cognition and attention.

Nieoullon A.

Prog Neurobiol. 2002 May;67(1):53-83. Review.

PMID:
12126656
8.

Neuropharmacological treatment of mental dysfunction in Parkinson's disease.

McNamara P, Durso R.

Behav Neurol. 2006;17(1):43-51. Review.

PMID:
16720959
9.

Treatment of Parkinson's disease: levodopa as the first choice.

Katzenschlager R, Lees AJ.

J Neurol. 2002 Sep;249 Suppl 2:II19-24. Review.

PMID:
12375059
10.

Cognitive impairments in Parkinson's disease.

Levin BE, Tomer R, Rey GJ.

Neurol Clin. 1992 May;10(2):471-85. Review.

PMID:
1584185
11.

Pharmacotherapy of Parkinson's disease.

Cohen MM, Scheife RT.

Am J Hosp Pharm. 1977 May;34(5):531-8. Review.

PMID:
326045
12.

[Cognitive dysfunction in Parkinson's disease].

Maruyama T.

Nihon Rinsho. 2000 Oct;58(10):2007-15. Review. Japanese.

PMID:
11068439
13.

[Cognitive impairment in patients with Parkinson disease].

Abe N, Mori E.

Brain Nerve. 2012 Apr;64(4):321-31. Review. Japanese.

PMID:
22481505
14.

What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition.

Yarnall AJ.

Neurodegener Dis Manag. 2014;4(2):127-36. doi: 10.2217/nmt.14.7. Review.

PMID:
24832030
15.

Practical therapy of Parkinson's disease.

Kurlan R.

Semin Neurol. 1987 Jun;7(2):160-6. Review. No abstract available.

PMID:
3332453
16.

Cognition and the inhibitory control of saccades in schizophrenia and Parkinson's disease.

Crawford TJ, Bennett D, Lekwuwa G, Shaunak S, Deakin JF.

Prog Brain Res. 2002;140:449-66. Review.

PMID:
12508608
17.

Dysfunction of the human memory systems: role of the dopaminergic transmission.

Dujardin K, Laurent B.

Curr Opin Neurol. 2003 Dec;16 Suppl 2:S11-6. Review.

PMID:
15129845
18.

New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease.

Calabresi P, Castrioto A, Di Filippo M, Picconi B.

Lancet Neurol. 2013 Aug;12(8):811-21. doi: 10.1016/S1474-4422(13)70118-2. Review.

PMID:
23867199
19.

Bladder function of patients with Parkinson's disease.

Sakakibara R, Tateno F, Nagao T, Yamamoto T, Uchiyama T, Yamanishi T, Yano M, Kishi M, Tsuyusaki Y, Aiba Y.

Int J Urol. 2014 Jul;21(7):638-46. doi: 10.1111/iju.12421. Epub 2014 Feb 27. Review.

20.

Nicotinic receptors and cognition in Parkinson's Disease: the importance of neuronal synchrony.

Forgacs PB, Bodis-Wollner I.

J Neural Transm (Vienna). 2004 Oct;111(10-11):1317-31. Epub 2004 Jun 30. Review.

PMID:
15480841
Items per page

Supplemental Content

Write to the Help Desk